TrialCancer2025

Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial.

Jing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.